<?xml version='1.0' encoding='utf-8'?>
<document id="21216137"><sentence text="Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study."><entity charOffset="10-20" id="DDI-PubMed.21216137.s1.e0" text="omeprazole" /><entity charOffset="63-73" id="DDI-PubMed.21216137.s1.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.21216137.s1.e0" e2="DDI-PubMed.21216137.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21216137.s1.e0" e2="DDI-PubMed.21216137.s1.e1" /></sentence><sentence text="Omeprazole is one of the most prescribed medications worldwide and within the class of proton pump inhibitors, it is most frequently associated with drug interactions"><entity charOffset="0-10" id="DDI-PubMed.21216137.s2.e0" text="Omeprazole" /></sentence><sentence text=" In vitro studies have shown that omeprazole can alter the function of metabolic enzymes and transporters that are involved in the metabolism of irinotecan, such as uridine diphosphate glucuronosyltransferase subfamily 1A1 (UGT1A1), cytochrome P-450 enzymes subfamily 3A (CYP3A) and ATP-binding cassette drug-transporter G2 (ABCG2)"><entity charOffset="34-44" id="DDI-PubMed.21216137.s3.e0" text="omeprazole" /><entity charOffset="145-155" id="DDI-PubMed.21216137.s3.e1" text="irinotecan" /><entity charOffset="165-184" id="DDI-PubMed.21216137.s3.e2" text="uridine diphosphate" /><pair ddi="false" e1="DDI-PubMed.21216137.s3.e0" e2="DDI-PubMed.21216137.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21216137.s3.e0" e2="DDI-PubMed.21216137.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21216137.s3.e0" e2="DDI-PubMed.21216137.s3.e2" /><pair ddi="false" e1="DDI-PubMed.21216137.s3.e1" e2="DDI-PubMed.21216137.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21216137.s3.e1" e2="DDI-PubMed.21216137.s3.e2" /></sentence><sentence text=" In this open-label cross-over study we investigated the effects of omeprazole on the pharmacokinetics and toxicities of irinotecan"><entity charOffset="68-78" id="DDI-PubMed.21216137.s4.e0" text="omeprazole" /><entity charOffset="121-131" id="DDI-PubMed.21216137.s4.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.21216137.s4.e0" e2="DDI-PubMed.21216137.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21216137.s4.e0" e2="DDI-PubMed.21216137.s4.e1" /></sentence><sentence text="" /><sentence text="Fourteen patients were treated with single agent irinotecan (600mg i"><entity charOffset="49-59" id="DDI-PubMed.21216137.s6.e0" text="irinotecan" /></sentence><sentence text="v" /><sentence text=", 90min) followed 3weeks later by a second cycle with concurrent use of omeprazole 40mg once daily, which was started 2weeks prior to the second cycle"><entity charOffset="72-82" id="DDI-PubMed.21216137.s8.e0" text="omeprazole" /></sentence><sentence text=" Plasma samples were obtained up to 55h after infusion and analysed for irinotecan and its metabolites 7-ethyl-10-hydroxycampothecin (SN-38), SN-38-glucuronide (SN-38G), 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin (NPC) and 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin (APC) by high-performance liquid chromatography (HPLC)"><entity charOffset="72-82" id="DDI-PubMed.21216137.s9.e0" text="irinotecan" /><entity charOffset="103-132" id="DDI-PubMed.21216137.s9.e1" text="7-ethyl-10-hydroxycampothecin" /><entity charOffset="134-139" id="DDI-PubMed.21216137.s9.e2" text="SN-38" /><entity charOffset="142-159" id="DDI-PubMed.21216137.s9.e3" text="SN-38-glucuronide" /><entity charOffset="161-167" id="DDI-PubMed.21216137.s9.e4" text="SN-38G" /><entity charOffset="170-231" id="DDI-PubMed.21216137.s9.e5" text="7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin" /><entity charOffset="233-236" id="DDI-PubMed.21216137.s9.e6" text="NPC" /><entity charOffset="242-319" id="DDI-PubMed.21216137.s9.e7" text="7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin" /><entity charOffset="321-324" id="DDI-PubMed.21216137.s9.e8" text="APC" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e0" e2="DDI-PubMed.21216137.s9.e0" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e0" e2="DDI-PubMed.21216137.s9.e1" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e0" e2="DDI-PubMed.21216137.s9.e2" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e0" e2="DDI-PubMed.21216137.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e0" e2="DDI-PubMed.21216137.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e0" e2="DDI-PubMed.21216137.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e0" e2="DDI-PubMed.21216137.s9.e6" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e0" e2="DDI-PubMed.21216137.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e0" e2="DDI-PubMed.21216137.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e1" e2="DDI-PubMed.21216137.s9.e1" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e1" e2="DDI-PubMed.21216137.s9.e2" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e1" e2="DDI-PubMed.21216137.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e1" e2="DDI-PubMed.21216137.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e1" e2="DDI-PubMed.21216137.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e1" e2="DDI-PubMed.21216137.s9.e6" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e1" e2="DDI-PubMed.21216137.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e1" e2="DDI-PubMed.21216137.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e2" e2="DDI-PubMed.21216137.s9.e2" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e2" e2="DDI-PubMed.21216137.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e2" e2="DDI-PubMed.21216137.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e2" e2="DDI-PubMed.21216137.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e2" e2="DDI-PubMed.21216137.s9.e6" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e2" e2="DDI-PubMed.21216137.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e2" e2="DDI-PubMed.21216137.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e3" e2="DDI-PubMed.21216137.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e3" e2="DDI-PubMed.21216137.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e3" e2="DDI-PubMed.21216137.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e3" e2="DDI-PubMed.21216137.s9.e6" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e3" e2="DDI-PubMed.21216137.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e3" e2="DDI-PubMed.21216137.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e4" e2="DDI-PubMed.21216137.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e4" e2="DDI-PubMed.21216137.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e4" e2="DDI-PubMed.21216137.s9.e6" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e4" e2="DDI-PubMed.21216137.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e4" e2="DDI-PubMed.21216137.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e5" e2="DDI-PubMed.21216137.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e5" e2="DDI-PubMed.21216137.s9.e6" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e5" e2="DDI-PubMed.21216137.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e5" e2="DDI-PubMed.21216137.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e6" e2="DDI-PubMed.21216137.s9.e6" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e6" e2="DDI-PubMed.21216137.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e6" e2="DDI-PubMed.21216137.s9.e8" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e7" e2="DDI-PubMed.21216137.s9.e7" /><pair ddi="false" e1="DDI-PubMed.21216137.s9.e7" e2="DDI-PubMed.21216137.s9.e8" /></sentence><sentence text=" Non-compartmental modelling was performed" /><sentence text=" Toxicities were monitored during both cycles" /><sentence text=" Paired statistical tests were performed with SPSS" /><sentence text="" /><sentence text="The exposure to irinotecan and its metabolites was not significantly different between both cycles"><entity charOffset="16-26" id="DDI-PubMed.21216137.s14.e0" text="irinotecan" /></sentence><sentence text=" Neither were there significant differences in the absolute nadir and percentage decrease of WBC and ANC, nor on the incidence and severity of neutropenia, febrile neutropenia, diarrhoea, nausea and vomiting when irinotecan was combined with omeprazole"><entity charOffset="213-223" id="DDI-PubMed.21216137.s15.e0" text="irinotecan" /><entity charOffset="242-252" id="DDI-PubMed.21216137.s15.e1" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.21216137.s15.e0" e2="DDI-PubMed.21216137.s15.e0" /><pair ddi="false" e1="DDI-PubMed.21216137.s15.e0" e2="DDI-PubMed.21216137.s15.e1" /></sentence><sentence text="" /><sentence text="Omeprazole 40mg did not alter the pharmacokinetics and toxicities of irinotecan"><entity charOffset="0-10" id="DDI-PubMed.21216137.s17.e0" text="Omeprazole" /><entity charOffset="69-79" id="DDI-PubMed.21216137.s17.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.21216137.s17.e0" e2="DDI-PubMed.21216137.s17.e0" /><pair ddi="false" e1="DDI-PubMed.21216137.s17.e0" e2="DDI-PubMed.21216137.s17.e1" /></sentence><sentence text=" This widely used drug can, therefore, be safely administered during a 3-weekly single agent irinotecan schedule"><entity charOffset="93-103" id="DDI-PubMed.21216137.s18.e0" text="irinotecan" /></sentence><sentence text="" /></document>